JMJoost M. Meijer

Joost M. Meijer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joost M. Meijer has a total of 227 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tissue‐bound and circulating IgA autoantibodies are linked to severe mucous membrane pemphigoid

    by Merve H. Erkayman, Barbara Horvath, Joost M. Meijer, Marieke C. Bolling, Gerton Lunter, Jeroen Bremer, Gilles F. H. Diercks

  • Open Access

    Clinical Characterization and Outcomes of Dupilumab for Pemphigoid Gestationis: A Case Series of Five Patients and Literature Review

    by Joost M. Meijer, Elise J. Leeman, Dominika Grabik, Lisette M. Prens, Klasiena Bouwman, Jelmer R. Prins, Sanne J. Gordijn, Mirthe H. Schoots, Maria C. Bolling, Gilles F. H. Diercks, et al.

    Treatment of pemphigoid gestationis (PG) mainly consists of systemic and potent topical corticosteroids. This retrospective case series describes patients with severe PG treated with dupilumab, including serological follow-up, and reviews all published cases. PG was confirmed by direct immunofluorescence (linear C3 and/or IgG deposition along the basement membrane zone) and serology (IgG epidermal staining on salt-split skin or anti-BP180 NC16A IgG ELISA). Pruritus, quality of life and anti-BP180 NC16A IgG and anti-BP180 NC16A IgE were monitored longitudinally. In 5 pregnant women, dupilumab was initiated with a 600 mg loading dose followed by 300 mg biweekly. Baseline pruritus was severe (NRS 8–10), with high DLQI scores (18–30). Blistering ceased within 1 week in 2 patients and within 4 weeks in 1. Two patients required weekly dosing for disease control. Systemic corticosteroids were discontinued in 3 patients and tapered to ≤10 mg/day in 2 before delivery. In one case, anti-BP180 IgG paralleled clinical improvement. Anti-BP180 IgE remained negative. All patients delivered healthy infants. In 10 reported cases, pruritus improved rapidly and systemic corticosteroids were tapered. These findings suggest dupilumab may be a promising corticosteroid-sparing option for PG, with rapid clinical response and a favourable safety profile, despite off-label use in pregnancy.

  • Open Access

    VEXAS syndrome as an underlying cause of disease in patients with Sweet syndrome

    by Josefien J.L. van Leengoed, Abraham Rutgers, Karina de Leeuw, André B. Mulder, Gilles F.H. Diercks, Marieke C. Bolling, Barbara Horváth, Joost M. Meijer

  • International development of Investigator Global Assessment scores for pemphigus

    by Dédée F. Murrell, Darby Boucher, Maryam Daneshpazhooh, Hamidreza Mahmoudi, Nika Kianfar, Shayan Dasdar, Marc Yale, Anna Wilson, Asli Bilgic, Soner Uzun, et al.

  • Open Access

    European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

    by A. Nanda, B. Tedbirt, C. Bodemer, M. C. Bolling, M. El Hachem, M. Nikolić, E. Benton, M. Caproni, D. De, D. Didona, et al.

    Introduction: Autoimmune blistering diseases (AIBDs) in children and adolescents present a major challenge in diagnosis and management because of their rarity and the presence of other differential diagnoses with blistering. They are potentially serious, and timely diagnosis and optimal management can help prevent morbidity related to both the diseases and their treatments. Methods: The Autoimmune Blistering Diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated evidence‐based, expert‐informed clinical guidelines for the diagnosis, treatment and monitoring of paediatric AIBDs. A writing group conducted a systematic review of the available literature on AIBDs in children and adolescents, and since there is limited strong evidence in the literature, recommendations were formulated by consensus over three rounds of structured feedback and revision by the Core Group and Expert Group of the task force (32 voting experts; >75% agreement threshold). Results: Although all AIBDs—including intra‐epidermal and subepidermal blistering disorders—are reported in children, linear IgA dermatosis (LAD) is the most common (42–83%). The diagnostic approach in the paediatric age group does not differ from that in adults. Treatment recommendations are tailored to paediatric patients, taking into account developmental pharmacokinetics, potential adverse effects and the impact of disease and therapy on quality of life. Conclusions: These guidelines provide the first comprehensive, paediatric‐focused framework for the diagnosis and management of AIBDs. Implementing the recommendations should harmonize care, reduce treatment‐related toxicity and improve quality of life for affected children while steering future research towards critical knowledge gaps.


  • Emerging Treatments in Pemphigus: Is Healing an Achievable Goal?

    by Barbara Horváth, Marjolein A. J. Hiel, Anne-Lise Strandmoe, Joost M. Meijer

    Pemphigus is a group of rare autoimmune blistering disorders affecting the skin and mucosal surfaces, caused by pathogenic immunoglobulin G (IgG) autoantibodies targeting desmosomal cadherins, specifically desmoglein-1 and desmoglein-3, which are key components of desmosomes. There are two main forms of pemphigus: pemphigus vulgaris (PV) and pemphigus foliaceus (PF), with PV being the most common. Pemphigus can be life-threatening owing to the progressive loss of the epidermal and epithelial barrier function. However, the introduction of rituximab, an anti-CD20 monoclonal antibody, has significantly improved treatment outcomes in pemphigus. This review provides a comprehensive overview of the current treatment landscape for pemphigus, highlighting both established and emerging therapeutic approaches.

  • Open Access

    Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments

    by Marjolein A J Hiel, Billal Tedbirt, Eva W H Korte, Maria C Bolling, Joost M Meijer, Phyllis I Spuls, Sjoukje van der Werf, Marc Yale, Pascal Joly, Barbara Horváth

    Background: Bullous pemphigoid (BP) is the most common autoimmune bullous disease. It is characterized by the development of tense blisters and pruritus. BP is a chronic disease that requires long-term treatment often associated with serious side effects. Developments in understanding the disease have led to novel treatment approaches evaluated in clinical trials. However, the pooling of trial data remains challenging due to inconsistent outcome reporting. Objectives: To provide an overview of BP outcome measurement over the last two decades by mapping and listing all previously reported treatment outcomes and outcome measurement instruments (OMIs). Methods: A large scoping review was performed using scientific databases and trial registries (January 2002–August 2025). Study selection and data extraction were performed independently by a minimum of two reviewers. Eligible study designs were clinical trials, prospective cohort studies and systematic reviews. Retrospective studies were excluded. All identified outcomes and OMIs were mapped into overarching domains for insights into outcome measurement trends over time, including the uptake of consensus definitions. Results: Eighty studies were included, consisting of clinical trials (n = 27), prospective cohort studies (n = 27) and systematic reviews (n = 26). A total of 659 outcomes were extracted verbatim and classified into 46 outcome domains across 10 outcome domain areas. Clinical response, safety and immunological response comprised a major part of outcome measurement. Moreover, steroid toxicity has increasingly been considered in clinical trials. Definitions and timepoints of clinical response varied considerably. An imbalance between patient-reported (PROs) and clinician-reported outcomes was revealed, with PROs being in the minority, as well as a diverging focus between primary analyses in clinical trials and secondary analyses in systematic reviews. OMIs used to measure patient impact and quality of life were mainly generic and only sparsely used. Conclusions: Over the past two decades, there has been considerable heterogeneity in reported outcomes and OMIs in BP research. Despite standardization efforts, most studies lack well-defined, consistent outcomes. Redefinition of some endpoints and a consensus-based approach towards outcome uniformity should bridge regulatory requirements with validated sensitive measurement and PROs. This approach would enhance the clinical relevance of trial endpoints while maintaining standardization, ultimately advancing research quality and therapeutic development.


  • Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review

    by Billal Tedbirt, Eva W. H. Korte, Marjolein A. J. Hiel, Joost M. Meijer, Maria C. Bolling, Phyllis I. Spuls, Sjoukje van der Werf, Marc Yale, Barbara Horváth, Pascal Joly

    Background Mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease that predominantly affects mucosae. Treatments for MMP often lack robust evidence and may be poorly tolerated, especially in elderly patients. Objective This scoping review aims to provide an overview of MMP outcome measurement of the last two decades by mapping and listing all previously reported outcomes and outcome measurement instruments (OMIs). Design A large scoping review was performed in scientific databases and trial registries (MEDLINE, Embase, CINAHL, PsycINFO, Cochrane CENTRAL, Web of Science, the International Clinical Trials Registry Platform and Clinicaltrials.gov) covering January 2002 to December 2023. Clinical trials, prospective cohort studies, and systematic reviews were included, while retrospective studies were excluded. Results Thirty-nine studies met the inclusion criteria, including 20 prospective cohort studies, 13 systematic reviews, and 6 clinical trials. A total of 285 outcomes were extracted verbatim and categorized into 29 domains and 9 overarching areas. The most commonly reported outcome areas were related to clinical response, safety, and resource use. The majority were investigator-reported outcomes (85%), with only 8% being patient-reported. Various OMIs (n = 14) were employed, including the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI) score and tools for assessing ocular impairment and quality of life. Reported outcomes and OMIs are very diverse due to the heterogeneity in the presentation of MMP. Conclusions The standardized use of consensus-based outcome definitions and high-quality instruments that consider the patient perspective is expected to increase the efficacy of future MMP research and can be achieved by consensus-based selection of outcomes and critical appraisal of the measurement properties of OMIs.


  • Open Access

    Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey

    by Eva W H Korte, Marjolein A J Hiel, Maria C Bolling, Patrick Dunn, Dédée F Murrell, Victoria P Werth, Marc Yale, Phyllis I Spuls, Joost M Meijer, Barbara Horváth

    This study analysed 32 failed drug development trials and surveyed 56 experts in the field of autoimmune bullous diseases to identify key challenges in bullous pemphigoid and pemphigus research. Clinical trials primarily failed due to unmet efficacy endpoints and recruitment difficulties, with experts highlighting the need to improve endpoint selection and patient enrolment strategies through international collaboration to develop more effective trial designs and advance new therapeutic options.

  • Bullous and Nonbullous Pemphigoid Associated With Prurigo Nodularis: Successful Treatment With Dupilumab

    by Marjolein A. J. Hiel, Laurens W. Barkema, Gilles F. H. Diercks, Maria C. Bolling, Jeroen Bremer, Barbara Horváth, Marie‐Louise A. Schuttelaar, Joost M. Meijer